Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study);La memantina en el tratamiento farmacológico de la enfermedad de Alzheimer moderadamente grave a grave en España (estudio MEMORY)

Revista de Neurologia

Volumn 51, Issue 9, 2010, Pages 525-534

  Agüera Ortiz, Luis F ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Alzheimer's disease; Effectiveness; Memantine; Safety; Treatment

Indexed keywords

MEMANTINE;

AGED; AGITATION; ALZHEIMER DISEASE; ARTICLE; CAREGIVER BURDEN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HALLUCINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROPSYCHIATRY; PRACTICE GUIDELINE; PRESCRIPTION; RETCHING; SIDE EFFECT; SPAIN;

EID: 78649860336     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.5109.2010246     Document Type: Article

References (34)

1. Riedijk SR, De Vugt ME, Duivenvoorden HJ, Niermeijer MF, Van Swieten JC, Verhey FRJ, et al. Caregiver burden, health-related quality of life and coping in dementia caregivers: a comparison of frontotemporal dementia and Alzheimer's disease. Dementia Cogn Dis 2006; 22: 405-12.
2. Rymer S, Salloway S, Norton L, Malloy P, Correia S, Monast D. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 2003; 16: 248-53. (Pubitemid 35434801)
3. Lobo A, Launer L, Fratiglioni L, Andersen K, Di Carlo A, Breteler M, et al. Prevalence of dementia and major subtypes in Europe: a collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000; 54 (Suppl 5): S4-9.
4. Raina P, Santaguida P, Ismaila A, Patterson C, Cowan D, Levine M, et al. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline. Ann Intern Med 2008; 148: 379-97.
5. Dantoine T, Auriacombe S, Sarazin M, Becker H, Pere JJ, Bourdeix I. Rivastigmine monotherapy and combination therapy with memantine in patients with moderately severe Alzheimer's disease who failed to benefit from previous cholinesterase inhibitor treatment. Int J Clin Pract 2006; 60: 110-8.
6. Danysz W, Parsons C, Möbius HJ, Stöffler A, Quack G. Neuroprotective and symptomatological action of memantine relevant for Alzheimer's Disease -a unified glutamatergic hypothesis on the mechanism of action. Neurotoxicity Res 2000; 2: 85-97.
7. Rossom R, Adityanjee, Dysken M. Efficacy and tolerability of memantine in the treatment of dementia. Am J Geriatr Pharmacother 2004; 2: 303-12.
8. Möbius HJ. Memantine: update on the current evidence. Int J Geriatr Psychiatry 2003; 18 (Suppl 1): S47-54.
9. Gil-Néciga E, Gobartt AL, Grupo de investigadores del estudio TRAIN. Patrón de tratamiento de la enfermedad de Alzheimer con inhibidores colinesterásicos (estudio TRAIN). Rev Neurol 2008; 46: 461-4.
10. Winblad B, Jones RW, Wirth Y, Stöffler A, Möbius HJ. Memantine in moderate to severe Alzheimer's disease: a metaanalysis of randomised clinical trials. Dementia Geriatr Cogn Disord 2007; 24: 20-7. (Pubitemid 46985287)
11. Folstein MF, Folstein SE, Mc Hugo PR. 'Mini mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
12. Guy W. Clinical global impressions (CGI). ECDEU assessment manual for psychopharmacology. Rockville, MD: National Institutes for Mental Health; 1976.
13. Sclan SG, Reisberg B. Functional assessment staging in Alzheimer's disease: reliability, validity and ordinality. Int Psychogeriatr 1992;4 (Suppl 1)): S55-69.
14. Reisberg B, Ferris SH, DeLeon MJ. The global deterioration scale of assessment of primary degenerative dementia. Br J Psychiatry 1982; 140: 566-72.
15. Galasko D, Corey-Bloom J, Thal LJ. Monitoring progression in Alzheimer's disease. J Am Geriatr Soc 1991; 39: 932-41.
16. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. Alzheimer Dis Assoc Disord 1997; 11 (Suppl 2): S33-9.
17. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308-14.
18. Boada M, Cejudo JC, Tárraga L, López OL, Kaufer D. Neuropsychiatric inventory questionnaire (NPI-Q): Spanish validation of an abridged form of the Neuropsychiatric Inventory (NPI). Neurologia 2002; 17: 317-23.
19. Peskind ER, Potkin SG, Pomara N, Ott BR, Graham SM, Olin JT, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry 2006; 14: 704-15.
20. Bakchine S, Loft H. Memantine treatment in patients with mild to moderate Alzheimer's disease: results of a randomised, double-blind, placebo-controlled 6-month study. J Alzheimer Dis 2008; 13: 97-107.
21. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol 2002; 17: 297-305. (Pubitemid 35283717)
22. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003; 348: 1333-41.
23. Van Dyck CH, Schmitt FA, Olin JT, for the Memantine MEM-MD-02 Study Group. A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil. Am J Geriatr Psychiatry 2006; 14: 428-37.
24. Sadik K, Wilcock G. The increasing burden of Alzheimer disease. Thoughts on the long-term management of Alzheimer Disease. Alzheimer Dis Assoc Disord 2003; 17 (Suppl 3): S75-9.
25. Aguglia E, Onor ML, Trevisiol M, Negro C, Saina M, Maso E. Stress in the caregivers of Alzheimer's patients: an experimental investigation in Italy. Am J Alzheimer Dis Other Dement 2004; 19: 248-52.
26. Croog SH, Burleson JA, Sudilovsky A, Baume RM. Spouse caregivers of Alzheimer patients: problem responses to caregiver burden. Aging Ment Health 2006; 10: 87-100.
27. Gaugler J, Kane R, Kane R, Newcomer R. The longitudinal effects of early behavior problems in the dementia caregiving career. Psychol Aging 2005; 20: 100-16.
28. Torti F, Gwyther L, Reed S, Friedman J, Schulman K. A multinational review of recent trends and reports in dementia caregiver burden. Alzheimer Dis Assoc Disord 2004; 18: 99-109.
29. Sink KM, Holden KF, Yaffe K. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence. JAMA 2005; 293: 596-608. (Pubitemid 40171242)
30. Farlow M, Tariot P, Grossberg G, Gergel I, Graham S, Jin J. Memantine/donepezil dual therapy is superior to placebo/donepezil therapy for treatment of moderate to severe Alzheimer's disease. Neurology 2003; 60 (Suppl 1): S412.
31. Tariot PN, Jakimovich L. Donepezil use for advanced Alzheimer's disease -a case study from a long-term care facility. J Am Med Dir Assoc 2003; 4: 216-9.
32. Grossberg GT, Edwards KR, Zhao Q. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease. J Clin Pharmacol 2006; 46 (Suppl 1): S17-26.
33. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004; 291: 317-24.
34. Qaseem A, Snow V, Cross JT Jr, Forciea MA, Hopkins R Jr, Shekelle P, et al. Current pharmacologic treatment of dementia: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2008; 148: 370-8.